Regeneron Pharmaceuticals (REGN) Net Margin (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Net Margin of 30.23% for Q2 2026, down 763.0% year-over-year from 4.56% in Q2 2025, and up 49.86% quarter-over-quarter from 20.17% in Q1 2026.
Regeneron Pharmaceuticals (REGN) Net Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Net Margin history runs 18 years deep, the most recent figure standing at 30.23% for Q2 2026.
- In Q2 2026, Net Margin fell 763.0% year-over-year to 30.23%; the TTM figure through Jun 2026 stood at 27.86% (down 350.0% YoY), while the FY2025 annual figure was 31.41%, up 34.0% from the prior year.
- Net Margin for Q2 2026 stood at 30.23%, up from 20.17% in the prior quarter.
- The five-year high for Net Margin was 1947.0% in Q1 2022, with the low at 20.17% in Q1 2026.
- The 5-year median for Net Margin is 30.44% (2026), against an average of 202.12%.
- The sharpest annual moves came in 2022 and 2023: Net Margin surged 190290 bps in 2022, then slumped 192114 bps in 2023.
- Regeneron Pharmaceuticals' Net Margin stood at 1197.1% in 2022, then tumbled by 97 bps to 33.77% in 2023, then slipped by 28 bps to 24.22% in 2024, then retreated by 10 bps to 21.74% in 2025, then soared by 39 bps to 30.23% in 2026.
- Business Quant data shows REGN's Net Margin at 30.23% in Q2 2026, 20.17% in Q1 2026, and 21.74% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,152.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.23% |
| Mar 31, 2026 | 20.17% |
| Dec 31, 2025 | 21.74% |
| Sep 30, 2025 | 38.89% |
| Jun 30, 2025 | 37.86% |
| Mar 31, 2025 | 26.70% |
| Dec 31, 2024 | 24.22% |
| Sep 30, 2024 | 36.03% |
| Jun 30, 2024 | 40.38% |
| Mar 31, 2024 | 22.96% |
| Dec 31, 2023 | 33.77% |
| Sep 30, 2023 | 29.97% |
| Jun 30, 2023 | 30.66% |
| Mar 31, 2023 | 25.86% |
| Dec 31, 2022 | 1,197.10% |
| Sep 30, 2022 | 44.81% |
| Jun 30, 2022 | 29.82% |
| Mar 31, 2022 | 1,947.00% |
| Dec 31, 2021 | 45.01% |
| Sep 30, 2021 | 47.27% |